IDT Extends the Operating Schedule at its Oligonucleotide Production Center
News Nov 30, 2005
Integrated DNA Technologies has announced that it is responding to the evolving needs of its biotech customers by extending the operating schedule at its main oligonucleotide production center effective immediately.
The new schedule (7:30am to 10:00pm CT) enables biotech researchers to order their products later each day, and still receive the benefits of IDT's swift order fulfillment process.
The new schedule also better serves the needs of sequencing houses and bio-science research labs by expanding the availability of IDT's live support and product ordering experts.
Combined with extensive online ordering options, including free oligo design and analysis software, IDT's enhanced service operations and support hours give scientists the technical assistance they need, whether placing, following up, or seeking guidance on orders.
The new service options are in line with IDT's ongoing commitment to quality and turnaround, which includes benefits such as - Every oligo synthesized is quality control tested by mass spectrometry.
The use of high-throughput advanced ESI Mass Spec technology allows greater quality control (QC) of oligos at any length.
Purified oligos receive additional QC by capillary electrophoresis and access to all quality control documents available free on the web. All oligos are twice quantitated by UV spectrophotometry
"Our new operating hours give researchers better options," noted Trey Martin, COO of Integrated DNA Technologies.
"We listened to the marketplace, and responded with improvements that reflect the pressures and demands on today's research labs."
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE
Over 130 Glaucoma Gene Variants Could Help Predict BlindnessNews
An international study has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness. The findings are an advance in the fight to tackle the incurable, degenerative condition, which has virtually no symptoms in the early stages, and could lead to a genetic-based screening program.READ MORE
Yeast Study Performs Hundreds of Simultaneous CRISPR EditsNews
A new technique which can alter hundreds of different genes at once in baker's yeast could greatly speed up CRISPR-Cas9 editing and offer a way to perform high-throughput functional genomics.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018